ClinicalTrials.gg
CompletedNCT06757010SUNRISE-PDUpdated Aug 11, 2026

A Study of NE3107 in Early Parkinson's

A Phase 2 interventional study of NE3107 and Placebo in Parkinsons Disease (PD), sponsored by BioVie Inc.. Completed at 4 sites in United States. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by BioVie Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.

Enrollment
453rd of 1,256
57 · median 36
Started
2025
with 77 others
Phase 2
234 of 1,649
25 open now
Registered
1,493rd of 1,649
by date

Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 453rd largest by enrollment of the 1,256 interventional ones that give a count, is one of 78 that started in 2025, is one of 234 in phase 2, and was the 1,493rd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

299 more — sign in →

All 304 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,649 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any form of levodopa or drug with similar activity. The main questions it aims to answer are:

  • Will bezisterim decrease movement symptoms of Parkinson's disease?
  • What medical problems do participants have when taking bezisterim?

Researchers will compare the effects of bezisterim treatment to placebo (a look-alike substance that contains no drug) to see if bezisterim works to treat movement symptoms of Parkinson's disease.

Participants will

  • have a physical examination that includes an electrocardiogram
  • take drug or placebo twice daily for four months
  • visit a clinical site or receive an at home visit seven times over the course of five months
03

Conditions studied

  • Parkinsons Disease (PD)

Browse trials for

Keywords

  • Treatment naïve Parkinson's
  • Early Parkinson's
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 45 years to 80 years of age
  • diagnosed with idiopathic Parkinson's Disease (PD) within 18 months
  • nearing the need for symptomatic therapy
  • agree to use measures
  • provide voluntary consent
  • willing to allow blood collection for DNA methylation analysis
  • pass all screening tests and procedures

Exclusion criteria

Exclusion Criteria:

  • has taken levodopa or another similar drug for the motor symptoms of PD
  • a known or strongly suspected familial cause for PD diagnosis
  • major mental health or physical illness
  • medical history of major mental or physical illness
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    NE3107

    Subjects will receive 20 mg NE3107 BID (twice daily administration; 40 mg daily) as oral capsules.

    Drug: NE3107

  • Placebo comparator
    Placebo

    Subjects will receive matching placebo capsules for oral administration BID (twice daily).

    Drug: Placebo

Interventions

  • DrugNE3107

    NE3107 20 mg BID

    Also known as: bezisterim

  • DrugPlacebo

    Placebo BID

06

What researchers measure

Primary outcomes

  1. Monocyte Lymphocyte Ratio (MLR)

    A unitless inflammatory biomarker calculated by dividing the absolute peripheral blood monocyte count by the absolute peripheral blood lymphocyte count, using values derived from clinical hematology (complete blood count with differential)

    Time frame: 12 Weeks

Secondary outcomes

  1. Change in Systemic Inflammation Response Index (SIRI)

    A unitless measure of systemic inflammation calculated as the product of the absolute blood neutrophil count and absolute blood monocyte count divided by the absolute blood lymphocyte count in samples obtained for clinical hematology testing.

    Time frame: 12 weeks

  2. Change in Neutrophil-to-Lymphocyte Ratio (NLR)

    A unitless measure of systemic inflammation calculated as the ratio of the absolute peripheral blood neutrophil count to the absolute peripheral blood lymphocyte count obtained from routine clinical hematology assessments.

    Time frame: 12 weeks

  3. Change in Systemic Immune-Inflammation Index (SII)

    A unitless composite measure of systemic inflammation and immune status calculated as the product of the absolute peripheral blood platelet count and neutrophil count divided by the absolute peripheral blood lymphocyte count obtained from routine clinical hematology assessments.

    Time frame: 12 weeks

  4. Change in Platelet-to-Lymphocyte Ratio (PLR)

    A unitless measure of systemic inflammation calculated as the ratio of the absolute peripheral blood platelet count to the absolute peripheral blood lymphocyte count obtained from routine clinical hematology assessments.

    Time frame: 12 weeks

  5. Change in Aggregate Index of Systemic Inflammation (AISI)

    A unitless composite measure of systemic inflammation calculated as the product of the absolute peripheral blood neutrophil count, monocyte count, and platelet count divided by the absolute peripheral blood lymphocyte count obtained from routine clinical hematology assessments.

    Time frame: 12 weeks

  6. Change in the Composite Benefit Score (CBS)

    Early Parkinson's Neuro-Inflammatory Composite-15 (EPNIC-15), a composite endpoint consisting of 15 clinically relevant motor and non-motor measures derived from MDS-UPDRS Parts I, II, and III and PDSS-2 assessments. Lower scores indicate improvement in Parkinson's disease symptoms.

    Time frame: 12 weeks

  7. Change in MDS-UPDRS modified Part III

    Change from baseline in MDS-UPDRS Modified Part III score, a clinician-rated measure of Parkinson's disease motor signs assessed using a modified Part III examination. The scale evaluates motor manifestations including speech, tremor, rigidity, bradykinesia, gait, posture, and postural stability. Higher scores indicate worse motor impairment.

    Time frame: 12 weeks

  8. Change in MDS-UPDRS Part II scores

    Change from baseline in MDS-UPDRS Part II score. MDS-UPDRS Part II assesses the impact of Parkinson's disease motor symptoms on activities of daily living, with higher scores indicating greater impairment and negative changes indicating improvement.

    Time frame: 12 weeks

  9. Change in MDS-UPDRS Part I scores

    Change from baseline in MDS-UPDRS Part I score. MDS-UPDRS Part I assesses non-motor experiences of daily living in Parkinson's disease, with higher scores indicating greater symptom burden and negative changes indicating improvement.

    Time frame: 12 weeks

  10. Change in MDS-UPDRS combined scores

    Change from baseline in the combined MDS-UPDRS score (Parts I + II + III). The combined score assesses overall Parkinson's disease burden across non-motor symptoms, activities of daily living, and motor signs, with higher scores indicating greater impairment and negative changes indicating improvement.

    Time frame: 12 weeks

  11. Change in PDQ-39 score

    Change from baseline in PDQ-39 total score. The Parkinson's Disease Questionnaire-39 (PDQ-39) assesses health-related quality of life across eight domains affected by Parkinson's disease. Higher scores indicate worse quality of life and negative changes indicate improvement.

    Time frame: 12 weeks

  12. Clinician's General Impression of Improvement (CGI-I)

    Clinician's Global Impression of Improvement (CGI-I) score. The CGI-I is a clinician-rated measure of overall change in a participant's condition compared with baseline, scored on a 7-point scale from 1 (very much improved) to 7 (very much worse). Lower scores indicate greater improvement.

    Time frame: 12 weeks

  13. Clinician's General Impression of Severity (CGI-S)

    Change from baseline in Clinician's Global Impression of Severity (CGI-S) score. The CGI-S is a clinician-rated measure of overall illness severity scored on a 7-point scale from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Higher scores indicate greater severity and negative changes indicate improvement.

    Time frame: 12 weeks

  14. Change in PARCOMS-Motor (modified to adjust for missing MDS-UPDRS Part III scores)

    Change from baseline in modified PARCOMS-Motor score. PARCOMS-Motor is a composite measure of Parkinson's disease motor symptoms derived from MDS-UPDRS motor assessments. The score was modified to adjust for missing MDS-UPDRS Part III data. Higher scores indicate greater motor impairment and negative changes indicate improvement

    Time frame: 12 weeks

Other outcomes

  1. Change in PDSS-2

    Change from baseline in PDSS-2 total score. The Parkinson's Disease Sleep Scale-2 (PDSS-2) assesses sleep disturbances and nocturnal symptoms associated with Parkinson's disease. Higher scores indicate worse sleep impairment and negative changes indicate improvement.

    Time frame: 12 weeks

  2. Change in DNA methylation

    Change from baseline in DNA methylation levels measured in peripheral blood samples. DNA methylation is an epigenetic biomarker associated with regulation of gene expression and cellular function.

    Time frame: 12 weeks

  3. Percent change in hematologic inflammatory biomarker indices

    Percent change from baseline in hematologic inflammatory biomarker indices (MLR, NLR, PLR, SIRI, SII, and AISI) derived from routine hematology testing. These indices are calculated from peripheral blood cell counts and are used as measures of systemic inflammation.

    Time frame: 12 weeks

  4. Change in plasma biomarkers of inflammation

    Change from baseline in plasma biomarkers of inflammation measured in peripheral blood samples. Plasma inflammatory biomarkers are indicators of immune and inflammatory activity that may reflect biological responses to treatment.

    Time frame: 12 week

  5. Interaction between baseline inflammation level and treatment effect on changes in circulating inflammatory indices

    Interaction between baseline inflammation level and treatment effect on changes in circulating inflammatory indices. Analysis of whether treatment effects on MLR, NLR, PLR, SIRI, SII, and AISI vary according to baseline systemic inflammation status.

    Time frame: 12 weeks

  6. Interaction between baseline inflammation level and treatment effect on changes in clinical endpoints

    Interaction between baseline inflammation level and treatment effect on changes in clinical endpoints. Analysis of whether treatment effects on clinical measures vary according to baseline systemic inflammation status.

    Time frame: 12 weeks

  7. Interaction between change in inflammation level and treatment effect on changes in circulating inflammatory indices

    Relationship between change in inflammation level and change from baseline in circulating inflammatory indices (MLR, NLR, PLR, SIRI, SII, and AISI). Analysis of whether treatment-related changes in systemic inflammation are associated with changes in circulating inflammatory biomarkers.

    Time frame: 12 week

  8. Interaction between change in inflammation level and treatment effect on changes in clinical endpoints

    Relationship between change in inflammation level and change from baseline in clinical endpoints. Analysis of whether treatment-related changes in systemic inflammation are associated with changes in clinical measures of Parkinson's disease.

    Time frame: 12 weeks

  9. Percent of subjects with any improvement from baseline as measured by CGI-I

    Percent of participants with improvement on CGI-I. Improvement is defined as a CGI-I score of 1 (very much improved), 2 (much improved), or 3 (minimally improved). The CGI-I is a clinician-rated measure of overall change from baseline

    Time frame: 12 weeks

  10. Percent of subjects with any improvement from baseline as measured by CGI-S

    Percent of participants with improvement in CGI-S score from baseline. Improvement is defined as any decrease from baseline in the Clinician's Global Impression of Severity (CGI-S) score. The CGI-S is a clinician-rated measure of overall illness severity scored from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Lower scores indicate less severe illness.

    Time frame: 12 weeks

  11. Biological and disease phenotype subgroup analyses for changes in circulating inflammatory biomarker indices

    Biological and disease phenotype subgroup analyses of changes in circulating inflammatory biomarker indices (MLR, NLR, PLR, SIRI, SII, and AISI). Analyses will evaluate whether treatment-related changes in inflammatory biomarkers differ across predefined biological and disease phenotype subgroups.

    Time frame: 12 weeks

  12. Biological and disease phenotype subgroup for changes in clinical endpoints

    Biological and disease phenotype subgroup analyses of changes in clinical endpoints. Analyses will evaluate whether treatment-related changes in clinical outcome measures differ across predefined biological and disease phenotype subgroups.

    Time frame: 12 weeks

07

Study locations

4 sites
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
  • Dent Neurologic
    Amherst, New York 14226, United States
  • Science 37 (Nationwide Site)
    Morrisville, North Carolina 27560, United States
  • NeuroScience Research Center, LLC
    Canton, Ohio 44718, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in May 2026, 13 months.

Of 96 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 13 months is below that.

Counting every sponsor, half of 201 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2024
First posted
Jan 3, 2025
StartActual
Mar 26, 2025
Primary completionActual
May 1, 2026
CompletionActual
May 31, 2026
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06757010
Lead sponsor
BioVie Inc.
Responsible party
Sponsor
First posted
Jan 3, 2025
Start date
Mar 26, 2025
Primary completion
May 1, 2026
Completion
May 31, 2026
Last update
Aug 11, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bezisterim

Start the discussion